AIFM2 and cancer: Killing of (cancer) cells by targeting FSP1 usually requires co-treatment with other types of canonical ferroptosis inducers5,19, such as the system Xc− inhibitor erastin, the glutamate cysteine ligase (GCL) inhibitor l-buthionine sulfoximine (BSO), and the GPX4 inhibitors (1S,3R)-RSL3 (RSL3), ML210 and FIN56, as well as the iron oxidation compound FINO2 (refs. 1,5,20–22), but not with compounds inducing other forms of cell death (Extended Data Fig. 1c–e).